The COLCOT trial published late last year showed that the anti-inflammatory colchicine was effective at significantly reducing MACE in those patients who had a previous myocardial infarction in the past 30 days. Another recent colchisine trial in acute coronary syndrome patients (COPS trial) showed a trend for reducing MACE but did not reach statistical significance. Today at ESC, another colchicine trial (LoDoCo2) is making headlines. LoDoCo2 trial was in those patients with stable cardiovascular disease and showed a very impressive and significant MACE reduction. Dr. Kausik Ray likes it too. A related LoDoCo2 proteome study found an impressive reduction in several circulating inflammatory proteins.